Rand Group
Crypto Trader & Investor, Building RR2 Capital, Early-Stage Investing
AI now makes early disease detection possible at scale, and catching disease early is always cheaper than treating it late. Detection names like Grail, Guardant, RadNet and Lunit win on distribution and reimbursement; grading names like Tempus, Veracyte, GE HealthCare and HeartFlow build data moats near treatment decisions. Monitoring via Natera, Personalis and iRhythm is the most asymmetric layer, a recurring subscription. NVIDIA gets paid whichever test wins. x.com
Reuters
Global News Agency
RADNET - ONRAD EXPECTED TO ADD $60 MILLION-$65 MILLION ADJUSTED EBITDA IN FIRST YEAR tradingview.com
AlvaMixedRadNet expects Onrad to add $60 million-$65 million of adjusted EBITDA in its first year, providing a measurable scale benefit, while funding the deal with $350 million in cash, 5 million shares, and a potential $210 million earnout.
Dow Jones
Real-Time Financial News Wire
RadNet said Onrad will be the foundation for a new reportable operating segment called Radiology Professional Services, the company said, adding that the deal would address growing U.S. demand for radiologists. tradingview.com
AlvaSupportsRadNet's acquisition of Onrad creates a Radiology Professional Services segment alongside its imaging operations, a company-stated effort to combine technology, radiology expertise, and imaging capacity to meet U.S. demand for radiologists.Reuters
Global News Agency
Tempus AI, Inc. :TEMPUS RECEIVES IVDR CERTIFICATION FOR XR RNA SEQUENCING FOR SOLID TUMOR PROFILING tradingview.com
AlvaSupportsIVDR certification gives Tempus a regulatory path for solid-tumor RNA profiling in Europe, supporting deployment of its testing near treatment decisions.Moonshots with Peter Diamandis
Technology Podcast Featuring Builders, Investors and Technologists
It turns out three point three percent of them have a cancer in their body they don't know about. ... We know it's much easier to treat a cancer when found early versus when found late. traffic.megaphone.fm
AlvaSupportsFinding previously unknown cancers in 3.3% of screened members supports the potential yield of early detection, alongside the clinical case for treating cancer earlier.Dow Jones
Real-Time Financial News Wire
According to a regulatory filing on Friday, the combined agreements provide Tempus with $192.5 million in total cash commitments over five years, consisting of $137.5 million directly from Bristol Myers, and $55 million from Pathos AI for 500,000 de-identified patient records. tradingview.com
AlvaSupportsThe filing puts $192.5 million of five-year cash commitments behind Tempus's oncology and neurological data deals, including $137.5 million from Bristol Myers and $55 million for 500,000 patient records, strengthening the case that its data assets can earn material revenue.Reuters
Global News Agency
SQUIBBBMS WILL LICENSE MULTIMODAL ONCOLOGY DATA FROM CO THROUGH 2031 TO SUPPORT BIOLOGICAL & CLINICAL INSIGHT tradingview.com
AlvaSupportsBristol Myers's license of Tempus's multimodal oncology data through 2031 supports the commercial value of its clinical data assets.Reuters
Global News Agency
Tempus will build a dataset from hundreds of thousands of patients with neurological disorders to help track outcomes and speed research into disease ... biologyPathos will license the data from Tempus under a five-year, $55 million tradingview.com
AlvaSupportsA five-year, $55 million license for Tempus's neurological patient and outcomes dataset provides concrete evidence that its clinical data have commercial value for AI-driven research.
Sarah Guo
Founder of Conviction, Startup Investor
OncoKB inside OpenEvidence means a doctor in a small rural town instantly has access to the same elite (and up to date) genomic expertise as the specialists at MSK. x.com
AlvaChallengesPutting MSK's genomic treatment guidance into OpenEvidence extends expert interpretation to community clinics, challenging how defensible proprietary grading expertise is near treatment decisions.Moonshots with Peter Diamandis
Technology Podcast Featuring Builders, Investors and Technologists
We know that when it comes to dementia, the conservative estimates are that forty five percent are entirely preventable. ... with the advanced testing we're doing at Fountain Life, one quarter of our members had advanced brain age. ... We saw that we improved that brain age by twenty six percent. That is a big number to show that the majority of those individuals were able actually to improve the brain age. traffic.megaphone.fm
AlvaSupportsFountain Life's advanced testing identified elevated brain age in a quarter of members, and subsequent improvement in that measure supports the case that early findings can guide preventive intervention.
John Coogan
Co-host of TBPN
There have been 60 plus companies since Theranos started that sold for over a $100,000,000 in that category. ... These companies get funded, no one reads their press releases and then they get sold for hundreds of millions of dollars and it's like, okay, cool. Yeah. Congrats. You made $500,000,000 doing another medical device. We know the playbook at this point. You you get some intellectual property. You build the device, kind of the supply chain, figure out the chemistry, get the FDA application in. It takes a decade for the FDA to actually approve it. We probably sell the company before then. media.transistor.fm
AlvaSupportsCoogan describes acquisitions before FDA approval as an established path for diagnostic-device startups, supporting the thesis's standalone-firm acquisition scenario.
Jason Wei
AI Researcher
AI will first master common and easy-to-see conditions and it will not be as good as experts at less-common diseases just because there is less data for that. ... AI will certainly be used as a triage tool at first, rather than full automation in one go. I would guess that this process from solid triage tool to full automation would take 3-5 years in the best case scenario, because training AI to get all the edge cases right will be bottlenecked by data collection of rare diseases, and also because radiology isn’t currently a focus for frontier labs. x.com
AlvaSupportsLimited rare-disease data makes comprehensive radiology automation harder, strengthening the thesis's case for data-rich imaging franchises.Jason Wei
AI Researcher
On top of all of this, the medical system is typically slower to adopt new technology and has more regulation compared to technology companies. There is legacy infrastructure and medical centers need to constantly support patients which makes it hard to integrate new technology. ... Moreover data access tends to be limited due to HIPAA, deidentification, IRBs, etc. So I think radiologists will be in demand for a while. x.com
AlvaChallengesSlow clinical adoption and restricted data access could delay the model improvement and deployment that scalable AI imaging diagnostics depend on, even as radiologists remain in demand.Jason Wei
AI Researcher
If there is essentially no cost or latency of interpreting an MRI, a physician can order many scans preemptively to better diagnose a case. ... I can imagine a world where people get 10 or 100x the number of scans they do today, largely for preventative care, if radiology were 10-100x cheaper. ... With good prediction algorithms, cancer may be detected months earlier than we can detect it now. x.com
AlvaSupportsCheaper AI interpretation could expand preventive scan volume substantially, strengthening the scalability case for imaging-based early detection; the earlier cancer detection remains a forecast contingent on better prediction algorithms.
